Ipilmumab and cranial radiation in metastatic melanoma patients: A case series and review

Journal for ImmunoTherapy of Cancer

Volumn 3, Issue 1, 2015, Pages

  Schoenfeld, Jonathan D ^a   Mahadevan, Anand ^b   Floyd, Scott R ^b,e   Dyer, Michael A ^d   Catalano, Paul J ^a   Alexander, Brian M ^a   McDermott, David F ^c   Kaplan, Irving D ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c Harvard Radiation Oncology Program ^*  (United States)

^d HARVARD RADIATION ONCOLOGY PROGRAM   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Abscopal effect; Brain metastases; Immunotherapy; Ipilimumab; Melanoma; Radiation; Stereotactic radiosurgery

Indexed keywords

IPILIMUMAB; RADIOACTIVE MATERIAL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; IMMUNOTHERAPY; MALE; MELANOMA METASTASIS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STEREOTACTIC RADIOSURGERY; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 84997207729     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-015-0095-8     Document Type: Article

References (21)

1. Fife KM, Colman MH, Stevens GN, Firth IC, Moon D, Shannon KF, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol. 2004;22(7):1293-300. doi: 10.1200/JCO.2004.08.140.
2. Bafaloukos D, Gogas H. The treatment of brain metastases in melanoma patients. Cancer Treat Rev. 2004;30(6):515-20. doi: 10.1016/j.ctrv.2004.05.001.
3. Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. The lancet oncology. 2012. doi: 10.1016/S1470-2045(12)70090-6
4. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-23. doi: 10.1056/NEJMoa1003466.
5. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517-26. doi: 10.1056/NEJMoa1104621.
6. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(10):925-31. doi: 10.1056/NEJMoa1112824.
7. Stamell EF, Wolchok JD, Gnjatic S, Lee NY, Brownell I. The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys. 2012;85(2):293-5. doi: 10.1016/j.ijrobp.2012.03.017.
8. Chandra R, Wilhite T, Balboni T, Alexander B, Spektor A, Ott PA et al. A Systematic Evaluation of Abscopal Responses following Radiotherapy in Patients with Metastatic Melanoma Treated with Ipilimumab. Oncoimmunology. 2015;in press. doi: 10.1080/2162402X.2015.1046028.
9. Barker CA, Postow MA, Khan SA, Beal K, Parhar PK, Yamada Y, et al. Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. Cancer Immunol Res. 2013;1(2):92-8. doi: 10.1158/2326-6066.CIR-13-0082. 2326-6066.CIR-13-0082.
10. Kiess AP, Wolchok JD, Barker CA, Postow MA, Tabar V, Huse JT, et al. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys. 2015;92(2):368-75. doi: 10.1016/j.ijrobp.2015.01.004.
11. Mathew M, Tam M, Ott PA, Pavlick AC, Rush SC, Donahue BR, et al. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Res. 2013;23(3):191-5. doi: 10.1097/CMR.0b013e32835f3d90.
12. Harmankaya K, Erasim C, Koelblinger C, Ibrahim R, Hoos A, Pehamberger H, et al. Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy. Med Oncol. 2011;28(4):1140-4. doi: 10.1007/s12032-010-9606-0.
13. Amin A, Depril V, Hamid O, Wolchok JD, Maio M, Neyns B et al. Evaluation of the effect of systemic corticosteroids for the treatment of immune-related adverse events (irAEs) on the development or maintenance of ipilimumab clinical activity. J Clin Oncol. 2009;27(15S).
14. Grimaldi AM, Simeone E, Giannarelli D, Muto P, Falivene S, Borzillo V, et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology. 2014;3:e28780. doi: 10.4161/onci.28780 2014ONCOIMM0023R.
15. Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst. 2013;105(4):265-65. doi: 10.1093/jnci/djs629.
16. Levy A, Chargari C, Cheminant M, Simon N, Bourgier C, Deutsch E. Radiation therapy and immunotherapy: implications for a combined cancer treatment. Crit Rev Oncol Hematol. 2012;85(3):278-87. doi: 10.1016/j.critrevonc.2012.09.001.
17. Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, Allison JP, et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res. 2005;11(2 Pt 1):728-34.
18. Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373-7. doi: 10.1038/nature14292. nature14292.
19. Knisely JPS, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang VLS. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg. 2012;117(2):227-33. doi: 10.3171/2012.5.JNS111929.
20. Shoukat S, Marcus D, Rizzo M, Lawson D, Liu Y, Khan M. Outcome with stereotactic radiosurgery (SRS) and ipilimumab (Ipi) for malignant melanoma brain metastases. J Clin Oncol. 2013;31(suppl; abstr 3032).
21. Tazi K, Hathaway A, Chiuzan C, Shirai K. Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery. Cancer Med. 2015;4(1):1-6. doi: 10.1002/cam4.315.